Nuwellis, Inc. (NASDAQ:NUWE – Get Free Report) saw a significant decline in short interest in the month of June. As of June 15th, there was short interest totaling 153,869 shares, a decline of 58.4% from the May 31st total of 369,455 shares. Currently, 5.8% of the shares of the company are sold short. Based on an average daily volume of 7,466,231 shares, the short-interest ratio is currently 0.0 days.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Nuwellis in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.
Get Our Latest Analysis on Nuwellis
Nuwellis Price Performance
Nuwellis (NASDAQ:NUWE – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($73.15) EPS for the quarter, missing analysts’ consensus estimates of ($35.00) by ($38.15). The firm had revenue of $2.40 million for the quarter, compared to analyst estimates of $2.09 million. Nuwellis had a negative return on equity of 32,351.83% and a negative net margin of 214.90%.
Institutional Trading of Nuwellis
A hedge fund recently raised its stake in Nuwellis stock. Sabby Management LLC raised its position in Nuwellis, Inc. (NASDAQ:NUWE – Free Report) by 149.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 89,685 shares of the company’s stock after buying an additional 53,791 shares during the period. Nuwellis comprises 0.2% of Sabby Management LLC’s investment portfolio, making the stock its 18th biggest position. Sabby Management LLC owned approximately 4.80% of Nuwellis worth $156,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 3.13% of the company’s stock.
About Nuwellis
Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.
The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.
Featured Articles
- Five stocks we like better than Nuwellis
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.
